Abstract：Objective：To observe the clinical effect of modified Yupinfeng Powder combined with montelukast sodium for bronchial asthma at the remission stage in adult. Methods：A total of 80 cases of adult patients with bronchial asthma at the remission stage were randomly divided into the control group and the observation group，40 cases in each group. The control group was given montelukast sodium，and the observation group was additionally treated with modified Yupingfeng powder based on the treatment of the control group. Both groups were treated for three months. The level of immune cells in serum， the disease severity and total clinical effect were observed and compared between the two groups. Results： After treatment，the values of CD4+ and CD4+/CD8+ in the two groups were decreased when compared with those before treatment (P＜0.05)，and the values of CD8+ were increased when compared with those before treatment(P＜0.05)；the improvement of the three indexes above in the observation group was more significant than that in the control group(P＜0.05). After treatment，the rate of disease severity was 2.5% in the observation group and 22.5% in the control group，the difference being significant(P＜0.05). The total effective rate was 97.5% in the observation group and 77.5% in the control group，the difference being significant(P＜0.05). Conclusion： The therapy of modified Yupinfeng powder combined with montelukast sodium has significant application effect in treating adult patients with bronchial asthma at the remission stage.